Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Core Insights - Lantheus Holdings, Inc. supports the CMS's proposed OPPS rule for 2025, which aims to improve payment for specialized diagnostic radiopharmaceuticals, enhancing patient access for Medicare beneficiaries [1][6] Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on enabling clinicians to diagnose and treat diseases effectively, thereby improving patient outcomes [15] - The company has been providing radiopharmaceutical solutions for over 65 years and operates in Massachusetts, Canada, and Sweden [15] Product Information - PYLARIFY (piflufolastat F 18) is a PSMA-targeted PET imaging agent that allows visualization of metastatic prostate cancer, demonstrating superior diagnostic performance [2][9] - PYLARIFY is the most ordered PSMA PET imaging agent in the U.S., with over 350,000 scans conducted across 48 states [2] Regulatory Developments - The proposed CMS rule suggests that diagnostic radiopharmaceuticals with a per day cost exceeding $630 will be paid separately, which is a shift from the current packaging policy [6] - The proposed rule will undergo a 60-day comment period ending on September 9, 2024, with the final rule expected in early November 2024, taking effect on January 1, 2025 [6]